Neviah Genomics Overview

  • Founded
  • 2012
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

Neviah Genomics General Information


Developer of novel biomarkers intended for the prediction of drug-induced toxicity. The company's biomarkers can predict toxicity profiles of drug candidates at an early stage of development, enabling doctors to minimize attrition and mitigating risk of late-stage drug failure.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Primary Office
  • 25 Maskit Street
  • Herzliya Pituach
  • Herzliya 46733
  • Israel
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Neviah Genomics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business Completed Out of Business
3. Accelerator/Incubator 30-Jun-2015 Completed Generating Revenue
2. Early Stage VC (Series A) 12-Jan-2015 Completed Generating Revenue
1. Joint Venture 25-Jun-2012 Completed Generating Revenue
To view Neviah Genomics’s complete valuation and funding history, request access »

Neviah Genomics Executive Team (1)

Name Title Board Seat Contact Info
Simone Botti Ph.D Acting Chief Executive Officer
To view Neviah Genomics’s complete executive team members history, request access »

Neviah Genomics Board Members (2)

Name Representing Role Since
Adam Sartiel Self Chairman 000 0000
You’re viewing 1 of 2 board members. Get the full list »